Identification of Differentially Expressed Transcripts and Pathways in Blood One Week and Six Months Following Implant of Left Ventricular Assist Devices

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Nov 9

PMID 24205042

Citations 6

Authors

Adam Mitchell

Weihua Guan

Rodney Staggs

Aimee Hamel

Sameh Hozayen

Neeta Adhikari

Suzanne Grindle

Snider Desir

Ranjit John

Jennifer L Hall

Peter Eckman

Affiliations

Soon will be listed here.

Abstract

Introduction: Continuous-flow left ventricular assist devices (LVADs) are an established therapy for patients with end-stage heart failure. The short- and long-term impact of these devices on peripheral blood gene expression has not been characterized, and may provide insight into the molecular pathways mediated in response to left ventricular remodeling and an improvement in overall systemic circulation. We performed RNA sequencing to identify genes and pathways influenced by these devices.

Methods: RNA was extracted from blood of 9 heart failure patients (8 male) prior to LVAD implantation, and at 7 and 180 days postoperatively. Libraries were sequenced on an Illumina HiSeq2000 and sequences mapped to the human Ensembl GRCh37.67 genome assembly.

Results: A specific set of genes involved in regulating cellular immune response, antigen presentation, and T cell activation and survival were down-regulated 7 days after LVAD placement. 6 months following LVAD placement, the expression levels of these genes were significantly increased; yet importantly, remained significantly lower than age and sex-matched samples from healthy controls.

Conclusions: In summary, this genomic analysis identified a significant decrease in the expression of genes that promote a healthy immune response in patients with heart failure that was partially restored 6 months following LVAD implant.

Citing Articles

Single-Cell RNA Sequencing Reveals Cardiac Fibroblast-Specific Transcriptomic Changes in Dilated Cardiomyopathy.

Russell-Hallinan A, Cappa O, Kerrigan L, Tonry C, Edgar K, Glezeva N Cells. 2024; 13(9.

PMID: 38727290 PMC: 11083662. DOI: 10.3390/cells13090752.

Antibody Response to SARS-CoV-2 Vaccination in Heart Failure Patients: Retrospective Single-Center Cohort Study.

Ergi D, Kahraman U, Akkus G, Durmaz S, Balcioglu O, Engin C Diagnostics (Basel). 2023; 13(22).

PMID: 37998596 PMC: 10670598. DOI: 10.3390/diagnostics13223460.

Cytomegalovirus reactivation in left ventricular assist device patients: case series and literature review.

Abohelwa M, Hassan M, Zahnan J, Sfeir P, El Zakhem A, Skouri H Eur Heart J Case Rep. 2021; 5(3):ytab090.

PMID: 33763628 PMC: 7976612. DOI: 10.1093/ehjcr/ytab090.

Circulating microbial RNA and health.

Leung R, Wu Y Sci Rep. 2015; 5:16814.

PMID: 26576508 PMC: 4649493. DOI: 10.1038/srep16814.

Mechanotransduction Mechanisms for Intraventricular Diastolic Vortex Forces and Myocardial Deformations: Part 2.

Pasipoularides A J Cardiovasc Transl Res. 2015; 8(5):293-318.

PMID: 25971844 PMC: 4519381. DOI: 10.1007/s12265-015-9630-8.

References

Rose E, Gelijns A, Moskowitz A, Heitjan D, Stevenson L, Dembitsky W . Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2002; 345(20):1435-43. DOI: 10.1056/NEJMoa012175. View

VanBuren P, Ma J, Chao S, Mueller E, Schneider D, Liew C . Blood gene expression signatures associate with heart failure outcomes. Physiol Genomics. 2011; 43(8):392-7. PMC: 3092336. DOI: 10.1152/physiolgenomics.00175.2010. View

Ankersmit H, Edwards N, Schuster M, John R, Kocher A, Rose E . Quantitative changes in T-cell populations after left ventricular assist device implantation: relationship to T-cell apoptosis and soluble CD95. Circulation. 1999; 100(19 Suppl):II211-5. DOI: 10.1161/01.cir.100.suppl_2.ii-211. View

Yu X, Kong Y, Dore L, Abdulmalik O, Katein A, Zhou S . An erythroid chaperone that facilitates folding of alpha-globin subunits for hemoglobin synthesis. J Clin Invest. 2007; 117(7):1856-65. PMC: 1904324. DOI: 10.1172/JCI31664. View

Turbpaiboon C, Wilairat P . Alpha-hemoglobin stabilizing protein: molecular function and clinical correlation. Front Biosci (Landmark Ed). 2009; 15(1):1-11. DOI: 10.2741/3601. View

Harris T, Waltman T, Carter S, Maisel A . Effect of prolonged catecholamine infusion on immunoregulatory function: implications in congestive heart failure. J Am Coll Cardiol. 1995; 26(1):102-9. DOI: 10.1016/0735-1097(95)00123-h. View

Dorn 2nd G, Kirshenbaum L . Cardiac reanimation: targeting cardiomyocyte death by BNIP3 and NIX/BNIP3L. Oncogene. 2009; 27 Suppl 1:S158-67. DOI: 10.1038/onc.2009.53. View

Diwan A, Wansapura J, Syed F, Matkovich S, Lorenz J, Dorn 2nd G . Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. Circulation. 2008; 117(3):396-404. PMC: 2538800. DOI: 10.1161/CIRCULATIONAHA.107.727073. View

Roberts A, Trapnell C, Donaghey J, Rinn J, Pachter L . Improving RNA-Seq expression estimates by correcting for fragment bias. Genome Biol. 2011; 12(3):R22. PMC: 3129672. DOI: 10.1186/gb-2011-12-3-r22. View

10.

Schleicher M, Brundin F, Gross S, Muller-Esterl W, Oess S . Cell cycle-regulated inactivation of endothelial NO synthase through NOSIP-dependent targeting to the cytoskeleton. Mol Cell Biol. 2005; 25(18):8251-8. PMC: 1234313. DOI: 10.1128/MCB.25.18.8251-8258.2005. View

11.

Yoshioka J, Chutkow W, Lee S, Kim J, Yan J, Tian R . Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. J Clin Invest. 2011; 122(1):267-79. PMC: 3248280. DOI: 10.1172/JCI44927. View

12.

Chen Y, Lewis W, Diwan A, Cheng E, Matkovich S, Dorn 2nd G . Dual autonomous mitochondrial cell death pathways are activated by Nix/BNip3L and induce cardiomyopathy. Proc Natl Acad Sci U S A. 2010; 107(20):9035-42. PMC: 2889094. DOI: 10.1073/pnas.0914013107. View

13.

Slaughter M, Rogers J, Milano C, Russell S, Conte J, Feldman D . Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009; 361(23):2241-51. DOI: 10.1056/NEJMoa0909938. View

14.

Blaxall B, Tschannen-Moran B, Milano C, Koch W . Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol. 2003; 41(7):1096-106. DOI: 10.1016/s0735-1097(03)00043-3. View

15.

Torre-Amione G, Stetson S, Youker K, Durand J, Radovancevic B, Delgado R . Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery. Circulation. 1999; 100(11):1189-93. DOI: 10.1161/01.cir.100.11.1189. View

16.

Trapnell C, Williams B, Pertea G, Mortazavi A, Kwan G, van Baren M . Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28(5):511-5. PMC: 3146043. DOI: 10.1038/nbt.1621. View

17.

Kimball P, Flattery M, McDougan F, Kasirajan V . Cellular immunity impaired among patients on left ventricular assist device for 6 months. Ann Thorac Surg. 2008; 85(5):1656-61. DOI: 10.1016/j.athoracsur.2008.01.050. View

18.

Hall J, Grindle S, Han X, Fermin D, Park S, Chen Y . Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol Genomics. 2004; 17(3):283-91. DOI: 10.1152/physiolgenomics.00004.2004. View

19.

Razeghi P, Mukhopadhyay M, Myers T, Williams J, Moravec C, Frazier O . Myocardial tumor necrosis factor-alpha expression does not correlate with clinical indices of heart failure in patients on left ventricular assist device support. Ann Thorac Surg. 2002; 72(6):2044-50. DOI: 10.1016/s0003-4975(01)03172-1. View

20.

Miller L, Pagani F, Russell S, John R, Boyle A, Aaronson K . Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007; 357(9):885-96. DOI: 10.1056/NEJMoa067758. View